Outset Medical's third quarter of 2025 saw a revenue of $36.2 million, a 10% increase year-over-year, driven by strong product revenue. Despite the revenue growth, the company reported a net loss of $23.1 million and a non-GAAP net loss of $18.5 million. Gross margin improved to 25.4%, and the Tablo installed base grew to 4,000 units.

Outset Medical delivered a strong second quarter, with net revenue increasing by 15% year-over-year to $31.4 million, driven by a significant 25% increase in Tablo console revenue. The company also improved its gross margin, reduced operating expenses by nearly 30%, and significantly decreased cash usage, demonstrating progress towards profitability.

Outset Medical reported a 6% increase in total revenue for the first quarter of 2025, reaching $29.8 million. The company saw significant growth in recurring revenue (consumables and services), which increased by 20% to $22.7 million. Gross margin improved to 37.2% on a GAAP basis and 37.6% on a non-GAAP basis. Net loss decreased significantly compared to the prior year, and net cash used in operating activities declined by 44%.

Outset Medical delivered a solid fourth quarter, exceeding prior guidance for revenue and significantly improving gross margin. The company saw strong recurring revenue growth driven by increased utilization of its Tablo system, positioning it for positive momentum into 2025.

Outset Medical reported a slight decrease in revenue compared to Q3 2023, but experienced sequential growth from Q2 2024. The company saw improvements in gross margin and achieved record recurring revenue. They also increased revenue guidance for the full year.

Outset Medical reported a revenue of $27.4 million for Q2 2024, a decrease compared to $36.0 million in Q2 2023. The company's gross margin improved to 35.7%. Net loss was $34.5 million, or $(0.66) per share.

Outset Medical reported a decrease in revenue for Q1 2024 to $28.2 million, compared to $33.5 million in Q1 2023. However, the company saw an increase in gross profit and gross margin, along with a reduction in operating expenses. The company reaffirmed its full year 2024 revenue guidance of $145 million to $153 million.